ES2873509T3 - Biomarcadores de neurotraumatismo y traumatoma de astrocitos - Google Patents

Biomarcadores de neurotraumatismo y traumatoma de astrocitos Download PDF

Info

Publication number
ES2873509T3
ES2873509T3 ES16790108T ES16790108T ES2873509T3 ES 2873509 T3 ES2873509 T3 ES 2873509T3 ES 16790108 T ES16790108 T ES 16790108T ES 16790108 T ES16790108 T ES 16790108T ES 2873509 T3 ES2873509 T3 ES 2873509T3
Authority
ES
Spain
Prior art keywords
tbi
injury
aldoc
kda
bdp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16790108T
Other languages
English (en)
Spanish (es)
Inventor
Ina-Beate Wanner
Joseph A Loo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California, San Diego
Original Assignee
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California, San Diego filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES2873509T3 publication Critical patent/ES2873509T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01259—[Fructose-bisphosphate aldolase]-lysine N-methyltransferase (2.1.1.259)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/40—Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES16790108T 2015-05-05 2016-05-05 Biomarcadores de neurotraumatismo y traumatoma de astrocitos Active ES2873509T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562157389P 2015-05-05 2015-05-05
PCT/US2016/031043 WO2016179426A1 (en) 2015-05-05 2016-05-05 Astrocyte traumatome and neurotrauma biomarkers

Publications (1)

Publication Number Publication Date
ES2873509T3 true ES2873509T3 (es) 2021-11-03

Family

ID=57218432

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16790108T Active ES2873509T3 (es) 2015-05-05 2016-05-05 Biomarcadores de neurotraumatismo y traumatoma de astrocitos

Country Status (7)

Country Link
US (4) US10557859B2 (enExample)
EP (1) EP3292414B1 (enExample)
JP (1) JP6839854B2 (enExample)
CN (1) CN107864671A (enExample)
ES (1) ES2873509T3 (enExample)
IL (1) IL255351A0 (enExample)
WO (1) WO2016179426A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3292414B1 (en) * 2015-05-05 2021-04-07 The Regents of the University of California Astrocyte traumatome and neurotrauma biomarkers
WO2018217792A1 (en) 2017-05-23 2018-11-29 Immunarray USA, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
US11988676B2 (en) * 2017-11-16 2024-05-21 Brainbox Solutions, Inc. Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
WO2019133717A1 (en) 2017-12-29 2019-07-04 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
EP4053559A1 (en) * 2021-03-01 2022-09-07 Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER) Methods for the measurement of protein c and activated protein c
CN119147761B (zh) * 2024-07-19 2026-01-06 复旦大学附属华山医院 Cryab在医学诊断和治疗中的应用
WO2026068747A1 (en) * 2024-09-26 2026-04-02 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Astrocytic phosphoprotein (pea-15) for use in the treatment and/or prevention of a neuronal disorder

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
GB0414798D0 (en) * 2004-07-01 2004-08-04 Paradigm Therapeutics Ltd Receptor
WO2007136617A2 (en) * 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
CA2715248A1 (en) * 2008-02-04 2009-08-13 Banyan Biomarkers, Inc. Process to diagnose or treat brain injury
JP5875514B2 (ja) 2009-06-19 2016-03-02 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカーアッセイ
KR101211280B1 (ko) * 2010-03-26 2012-12-11 가톨릭대학교 산학협력단 신규한 뇌손상 질환 진단용 마커 및 이의 용도
WO2011147981A2 (en) * 2010-05-28 2011-12-01 Mind-Nrg Sa Neuregulin isoforms, neuregulin polypeptides and uses thereof
WO2012051519A2 (en) 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
CA2943396A1 (en) 2014-04-07 2015-10-15 Iron Horse Diagnostics, Inc. Traumatic brain injury and neurodegenerative biomarkers, methods, and systems
WO2016048488A1 (en) 2014-09-25 2016-03-31 Oxeia Biopharmaceuticals, Inc. Methods of treating traumatic brain injury
EP3292414B1 (en) * 2015-05-05 2021-04-07 The Regents of the University of California Astrocyte traumatome and neurotrauma biomarkers

Also Published As

Publication number Publication date
US20260110699A1 (en) 2026-04-23
IL255351A0 (en) 2017-12-31
JP2018523092A (ja) 2018-08-16
US10557859B2 (en) 2020-02-11
JP6839854B2 (ja) 2021-03-17
US20180364259A1 (en) 2018-12-20
EP3292414B1 (en) 2021-04-07
CN107864671A (zh) 2018-03-30
US12339289B2 (en) 2025-06-24
EP3292414A4 (en) 2018-09-26
US20200278359A1 (en) 2020-09-03
US11249094B2 (en) 2022-02-15
EP3292414A1 (en) 2018-03-14
WO2016179426A1 (en) 2016-11-10
US20220299531A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US12339289B2 (en) Astrocyte traumatome and neurotrauma biomarkers
ES2532229T3 (es) Biomarcadores de seguridad renal predictiva y señales de biomarcadores para monitorizar la función renal
ES2665245T3 (es) Proceso de detección de biomarcador y ensayo de estado neurológico
Pelinka et al. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome
CA3159379A1 (en) Biomarkers and uses thereof for diagnosing the silent phase of alzheimer's disease
ES2712060T3 (es) Métodos de diagnóstico para el glaucoma
ES2630905T3 (es) Proteínas inmunitarias innatas como biomarcadores para lesiones del SNC
ES2702183T3 (es) Identificación y monitorización de inmunoglobulinas monoclonales por masa molecular
ES2706534T3 (es) Método para ayudar al diagnóstico diferencial del accidente cerebrovascular
ES2689753T3 (es) Fármaco de diagnóstico y método de diagnóstico para la enfermedad de Alzheimer
ES2617918T9 (es) Biomarcador para trastornos mentales, incluyendo trastornos cognitivos, y método de utilización de dicho biomarcador para la detección de trastornos mentales, incluyendo los trastornos cognitivos
US11726100B2 (en) Method of treating large vessel occlusion stroke
US9977036B2 (en) Diagnostic markers for multiple sclerosis
CA2718955C (en) Methods and kits for the differential diagnosis of alzheimer's disease versus frontotemporal dementia and for the diagnosis of frontotemporal dementia comprising fas-l and ck 18 as biomarkers
US20180120328A1 (en) Biomarker for psychiatric and neurological disorders
ES2975228T3 (es) Derivados de GFAP para el diagnóstico de accidente cerebrovascular
ES2400255T3 (es) Procedimiento in vitro para la diagnosis y la diagnosis precoz de enfermedades neurodegenerativas
ES2921180T3 (es) Método para medir la toxicidad del CSF humano
N Antonopoulos et al. Biomarkers in silent traumatic brain injury
WO2010005077A1 (ja) パーキンソン病の疾患関連たんぱく質およびその使用
ES2332136T3 (es) Evaluacion de daño neuronal a partir de muestras de sangre.
ES2389199B1 (es) Método de diagnóstico de la enfermedad de alzheimer que emplea sfrp1 como biomarcador.
ES2706539T3 (es) Método de diagnóstico in vitro de la Enfermedad de Alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo
US20260063642A1 (en) Methods for Assaying a Bodily Sample of a Subject
US20200057078A1 (en) Melanotransferrin for use in the diagnosis of parkinson`s disease